Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMevastatin is an inhibitor of HMG-CoA reductase; decreases cholesterol biosynthesis, in vitro and in vivo. Induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Inactive lactam prodrug of mevastatin hydroxy acid, naturally bioactivated in vivo following oral administration.
分子量 | 390.52 |
公式 | C23H34O5 |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 73573-88-3 |
PubChem ID | 64715 |
InChI Key | AJLFOPYRIVGYMJ-INTXDZFKSA-N |
Smiles | [H][C@@]12C(C=C[C@H](C)[C@@]([H])2CC[C@@]3([H])OC(C[C@]([H])(O)C3)=O)=CCC[C@@H]1OC([C@@H](C)CC)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
ethanol | 9.76 | 25 温和加热 | |
DMSO | 19.53 | 50 温和加热 |
以下数据基于产品分子量 390.52。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.5 mM | 5.12 mL | 25.61 mL | 51.21 mL |
2.5 mM | 1.02 mL | 5.12 mL | 10.24 mL |
5 mM | 0.51 mL | 2.56 mL | 5.12 mL |
25 mM | 0.1 mL | 0.51 mL | 1.02 mL |
参考文献是支持产品生物活性的出版物。
Amin-Hanjani et al (2001) Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 980 PMID: 11283400
Cohen et al (1984) Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density lipoprotein-receptor activity in the human hepatoma cell line Hep G2. Biochem.J. 222 35 PMID: 6089762
Wachtershauser et al (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22 1061 PMID: 11408350
If you know of a relevant reference for Mevastatin, please let us know.
关键词: Mevastatin, Mevastatin supplier, HMG-CoA, reductases, inhibitors, inhibits, statins, Compactin, Reductase, 1526, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 Mevastatin 的部分引用包括:
Brown and Price (2007) Characterization of Salmonella enterica serovar Typhimurium DT104 invasion in an epithelial cell line (IPEC J2) from porcine small intestine. Vet Microbiol 120 328 PMID: 17157450
Roche et al (2018) Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation. J Cell Biol 217 3560 PMID: 30054450
Kant et al (2019) Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons. Cell Stem Cell 24 363 PMID: 30686764
Vergnes et al (2016) SREBP-2-deficient and hypomorphic mice reveal roles for SREBP-2 in embryonic development and SREBP-1c expression. J Lipid Res 57 410 PMID: 26685326
Song et al (2019) A dynamic view of the proteomic landscape during differentiation of ReNcell VM cells, an immortalized human neural progenitor line. Sci Data 6 190016 PMID: 30778261
Leznicki et al (2018) Expansion of DUB functionality generated by alternative isoforms - USP35, a case study. J Cell Sci 131 PMID: 29685892
您是否知道使用了 Tocris Mevastatin 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review Mevastatin and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.